Finally, miRNAs not only provide us with information regarding the molecular mechanism underlying the therapeutic effects of certain anxiolytic drugs (miR-34a regulates GRM7 levels after lithium/VPA treatment [68] and miR-16 regulates SERT expression in response to Prozac [116]) but also presents novel therapeutic targets for the treatment of anxiety disorders, either through directly targeting the miRNA itself or by targeting the targets of those miRNAs that have been associated with anxiety disorders. The gene discussed is GRM7; the disease is anxiety disorder.